Document is current
Any future updates will be listed below
-
Authors
Pisera, Alexander ‘Olek’
Liu, Chang C. https://orcid.org/0000-0002-3290-2880
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM136297)
Paul and Daisy Soros Fellowships for New Americans
- License Information
-
More Information
Article History
Received: 14 December 2024
Accepted: 9 June 2025
First Online: 14 July 2025
Competing interests
: C.C.L. is a co-founder of K2 Therapeutics, which uses OrthoRep in antibody engineering and evolution. The other authors declare no competing interests.
